Davies BR - Search Results

1

Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.

Ezell SA, Wang S, Bihani T, Lai Z, Grosskurth SE, Tepsuporn S, Davies BR, Huszar D, Byth KF. Ezell SA, et al. Among authors: davies br. Oncotarget. 2016 Feb 23;7(8):9163-74. doi: 10.18632/oncotarget.7036. Oncotarget. 2016. PMID: 26824321 Free PMC article.

2

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard SM, Smith PD. Holt SV, et al. Among authors: davies br. Cancer Res. 2012 Apr 1;72(7):1804-13. doi: 10.1158/0008-5472.CAN-11-1780. Epub 2012 Jan 23. Cancer Res. 2012. PMID: 22271687

3

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.

Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, Li J, Gao B, Ji Q, Maynard J, Ricketts SA, Cross D, Cosulich S, Chresta CC, Page K, Yates J, Lane C, Watson R, Luke R, Ogilvie D, Pass M. Davies BR, et al. Mol Cancer Ther. 2012 Apr;11(4):873-87. doi: 10.1158/1535-7163.MCT-11-0824-T. Epub 2012 Jan 31. Mol Cancer Ther. 2012. PMID: 22294718 Clinical Trial.

4

PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.

Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, Linch DC, Khwaja A. Meja K, et al. Among authors: davies br. Br J Haematol. 2014 Oct;167(1):69-79. doi: 10.1111/bjh.13013. Epub 2014 Jun 30. Br J Haematol. 2014. PMID: 24975213 Free article.

5

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM. Marques RB, et al. Among authors: davies br. Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12. Eur Urol. 2015. PMID: 25220373

6

Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.

Hancox U, Cosulich S, Hanson L, Trigwell C, Lenaghan C, Ellston R, Dry H, Crafter C, Barlaam B, Fitzek M, Smith PD, Ogilvie D, D'Cruz C, Castriotta L, Wedge SR, Ward L, Powell S, Lawson M, Davies BR, Harrington EA, Foster E, Cumberbatch M, Green S, Barry ST. Hancox U, et al. Among authors: davies br. Mol Cancer Ther. 2015 Jan;14(1):48-58. doi: 10.1158/1535-7163.MCT-14-0406. Epub 2014 Nov 14. Mol Cancer Ther. 2015. PMID: 25398829

7

Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.

Yates JW, Dudley P, Cheng J, D'Cruz C, Davies BR. Yates JW, et al. Among authors: davies br. Cancer Chemother Pharmacol. 2015 Aug;76(2):343-56. doi: 10.1007/s00280-015-2795-7. Epub 2015 Jun 20. Cancer Chemother Pharmacol. 2015. PMID: 26092323

8

Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.

Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, Davies BR. Crafter C, et al. Among authors: davies br. Int J Oncol. 2015 Aug;47(2):446-54. doi: 10.3892/ijo.2015.3062. Epub 2015 Jun 22. Int J Oncol. 2015. PMID: 26095475 Free PMC article.

9

AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.

Ribas R, Pancholi S, Guest SK, Marangoni E, Gao Q, Thuleau A, Simigdala N, Polanska UM, Campbell H, Rani A, Liccardi G, Johnston S, Davies BR, Dowsett M, Martin LA. Ribas R, et al. Among authors: davies br. Mol Cancer Ther. 2015 Sep;14(9):2035-48. doi: 10.1158/1535-7163.MCT-15-0143. Epub 2015 Jun 26. Mol Cancer Ther. 2015. PMID: 26116361

10

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

O'Neill D, Jones D, Wade M, Grey J, Nakjang S, Guo W, Cork D, Davies BR, Wedge SR, Robson CN, Gaughan L. O'Neill D, et al. Among authors: davies br. Oncotarget. 2015 Sep 22;6(28):26029-40. doi: 10.18632/oncotarget.4347. Oncotarget. 2015. PMID: 26267320 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

130 results

Search Page